Drug Trial Radar · NCT07243340
A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Apr 3, 2026
Primary completion
Dec 15, 2027
Study completion Dec 15, 2028
Sponsor
- Lead sponsor
- ImmVira Pharma Co. LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study includes phase I dose escalation part and phase IIa dose expansion part. The goal of this clinical trial is to learn if C5252 treatment is safe and well tolerated in patients with intracranial tumor and to learn preliminary efficacy of C5252. In this study, participants will be given single or multiple doses of C5252 according to protocol followed by toxicity observation, safety follow-up and long-term follow-up.
Conditions
- Glioma, Malignant
Interventions
Herpes Virus C5252 InjectionBiological
C5252 will be administered at designed dose level.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Incidence of adverse eventTime frame: Up to 30 days after completion of treatment
- Phase I: Determine the MTD/RP2DTime frame: up to 4 weeks
- Phase II: Overall SurvivalTime frame: Up to 2 years
- Phase II: OS rateTime frame: Up to 2 years after first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.